Company Description
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors.
The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L.
The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019.
Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Country | United States |
| Founded | 2006 |
| IPO Date | Oct 16, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | Pietro Bersani CPA, J.D. |
Contact Details
Address: 7707 Fannin St., Suite 140 Houston, Texas 77054 United States | |
| Phone | 832-968-4888 |
| Website | kiromic.com |
Stock Details
| Ticker Symbol | KRBP |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.00 |
| CIK Code | 0001792581 |
| CUSIP Number | 497634105 |
| ISIN Number | US4976342042 |
| Employer ID | 46-4762913 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pietro Bersani CPA, J.D. | Chief Executive Officer and Director |
| Brian Hungerford | Chief Financial Officer |
| Dr. Leonardo Mirandola Ph.D. | Chief Scientific Officer and Interim Chief Operating Officer |
| Dr. Scott Dahlbeck M.D., Pharm.D., PharmD | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | DEF 14A | Other definitive proxy statements |
| May 10, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 7, 2024 | PRE 14A | Other preliminary proxy statements |
| May 6, 2024 | 8-K | Current Report |
| Apr 19, 2024 | 8-K | Current Report |
| Apr 10, 2024 | RW | Filing |
| Apr 5, 2024 | 8-K | Current Report |
| Apr 2, 2024 | 8-K | Current Report |
| Mar 21, 2024 | 10-K/A | [Amend] Annual report |